Airna has initiated a Phase 1 clinical trial for AIR-001, an RNA-editing therapeutic targeting alpha-1 antitrypsin deficiency (AATD). The open-label RepAIR1 study (NCT07431112) aims to assess the safety, pharmacokinetics, and pharmacodynamics of AIR-001 in adults with the PiZZ genotype, enrolling approximately 54 patients across multiple countries, including Australia and the UK. The trial has received regulatory approval in various jurisdictions, and the U.S. FDA has granted orphan drug designation to this innovative candidate.

The significance of AIR-001 lies in its mechanism: it utilizes a subcutaneous GalNAc oligonucleotide to recruit endogenous ADAR enzymes, enabling the editing of SERPINA1 mRNA to correct the PiZ mutation. This approach aims to restore functional AAT levels, potentially addressing both lung and liver complications associated with AATD. Preclinical data suggest that AIR-001 may significantly enhance functional AAT levels, positioning it as a best-in-class candidate for treating this genetic disorder.

The implications of this trial extend beyond AATD, as it may shift paradigms in RNA-editing therapies. Success in this trial could accelerate the development timelines for similar RNA-editing strategies targeting other genetic disorders, highlighting the therapeutic potential of reversible and repeatable interventions in the field of longevity and healthspan research. As the trial progresses, it will be critical to monitor not only the safety and efficacy outcomes but also the broader impact on RNA-based therapeutics in clinical settings.

Source: longevity.technology